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Abstract
Introduction
The prevalence of type 2 diabetes (T2D) and the metabolic syndrome (MetS) is increasing
and several studies suggested an involvement of DNA methylation in the development of
these metabolic diseases. This study was designed to investigate if differential DNA methyl-
ation in blood can function as a biomarker for T2D and/or MetS.
Methods
Pyrosequencing analyses were performed for the candidate genes KCNJ11, PPARγ,
PDK4, KCNQ1, SCD1, PDX1, FTO and PEG3 in peripheral blood leukocytes (PBLs) from
25 patients diagnosed with only T2D, 9 patients diagnosed with T2D and MetS and 11 con-
trol subjects without any metabolic disorders.
Results
No significant differences in gene-specific methylation between patients and controls were
observed, although a trend towards significance was observed for PEG3. Differential meth-
ylation was observed between the groups in 4 out of the 42 single CpG loci located in the
promoters regions of the genes FTO, KCNJ11, PPARγ and PDK4. A trend towards a posi-
tive correlation was observed for PEG3 methylation with HDL cholesterol levels.
Discussion
Altered levels of DNA methylation in PBLs of specific loci might serve as a biomarker for
T2D or MetS, although further investigation is required.
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Introduction
The prevalence of metabolic diseases has been rising worldwide as a consequence of the
increasing rate of obesity and sedentary lifestyles[1]. Two prominent metabolic diseases are
diabetes mellitus type 2 (T2D) and the metabolic syndrome (MetS). While T2D encompasses
insulin resistance, MetS encompasses a more complex network of risk factors and symptoms
that predisposes to diabetes and cardiovascular diseases. The symptoms of MetS include ele-
vated blood pressure, dyslipidemia, raised fasting glucose and central obesity[1]. The main risk
factors for metabolic diseases, namely low physical activity, genetic predisposition and poor
diet[2], are also factors which can modify DNA methylation and other epigenetic patterns
[3,4].
DNA methylation is a biological process by which a methyl group is added to a DNA nucle-
otide, without changing the underlying DNA sequence[5]. The state of DNA methylation of
CpG loci near gene promoters, CpG shores and gene bodies were found to be associated with
transcriptional activity and gene expression[6–9]. DNA methylation is thought to play a role
in regulating human metabolism[10] and epigenetic changes have been suggested to partici-
pate in the development of T2D[11]. Several studies have observed differential methylation in
T2D and MetS patients compared to control subjects in adipose tissues, muscles and pancre-
atic islets in genes important for human metabolism[12–16]. Overexpression or silencing of
some of these differentially methylated genes resulted for example in reduced β cell prolifera-
tion or glucose-stimulated insulin secretion[17,18]. However, to make DNA methylation levels
useful as biomarker for metabolic disorders it is essential to identify markers reflected in easily
accessible tissues such as blood. Bacos et al reported a 60% overlap between genes associated
with age-related changes in DNA methylation in both leucocytes and pancreatic islets and
some of these differentially methylated genes affected insulin secretion[19] and Vanderjagt
et al reported that differential DNA methylation in blood was observed in the pre-T2D state
[20], suggesting a potential of DNA methylation early in the development of T2D.
We designed this study to investigate gene-specific methylation levels in peripheral blood
leukocytes (PBLs) of patients diagnosed with T2D or MetS. The aim of this study was to inves-
tigate whether differential DNA methylation was present in PBL of patients diagnosed with
either T2D or MetS compared to a control group, and whether altered levels of DNA methyla-
tion in blood may function as a biomarker for these metabolic conditions. We used a candidate
gene approach including 8 genes that have a functional relevance in metabolic processes, such
as glucose metabolism, fatty acid storage, fatty acid metabolism, pancreatic development and β
cell maturation[21–26]. Five of these genes, FTO,KCNQ1, PDK4, PDX1 and PPARγ, were pre-
viously identified to be differentially methylated in adipose tissues, muscles and/or pancreatic
islets from diabetic patients [12–16].
Methods
Study population
All participants were recruited at the Freiburg University Medical Center Diabetes Clinic and
a written informed consent was obtained from all the participants included in this study. The
study was approved by the Albert-Ludwigs-Universita¨t Freiburg ethics committee and Institu-
tional Review Board. Measurements of all metabolic traits were performed by trained physi-
cians at the University Medical Center Freiburg Diabetes Clinic, according to their validated
guidelines. The measurements were performed after an overnight fast.
All participants were between 45 and 85 years of age. This study included 11 participants
without any metabolic condition and 34 metabolic patients, from which 25 participants were
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diagnosed with only T2D, and 9 participants were diagnosed with both MetS and T2D. All
patients diagnosed with MetS in our study were diagnosed with T2D and had central obesity,
plus at least one of the following three factors which defines MetS; elevated triglycerides150
mg/dL (1.7 mmol/L) or specific treatment for this lipid abnormality; reduced HDL cholesterol
<40 mg/dL (1.03 mmol/L) in males and< 50 mg/dL (1.29 mmol/L) in females or specific
treatment for this lipid abnormality; or raised systolic blood pressure130 or diastolic blood
pressure85 mmHg or treatment of previously diagnosed hypertension[27]. None of the par-
ticipants were diagnosed with another condition, such as cancer or autoimmune disease. Fur-
ther characteristics of the study participants can be found in Table 1.
Age distribution, gender distribution and blood pressure were not significantly different
between the groups of participants. As expected, statistically significant differences were
observed between the participants diagnosed with T2D and/or MetS and the control group for
TG levels, HDL cholesterol levels, waist circumcise and blood glucose levels (p0.05)(Table 1).
TG levels, HDL cholesterol levels, blood glucose levels and waist measurements were corre-
lated with each other, such that an individual with low levels of HDL cholesterol also had high
levels of fasting blood glucose, high TG levels, and a high waist circumference. Similar correla-
tions were found between systolic blood pressure and both diastolic blood pressure and blood
glucose levels (p<0.05) (S1 Fig).
DNA preparation and PCR conditions
DNA was extracted from PBLs using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
and genomic DNA was treated with bisulphite salt using the EZ DNA Methylation Gold kit
Table 1. Study participant characteristics. Characteristics of the participants in this study are shown as median (range). The participants were divided into
three subgroups: control subjects, T2D patients and MetS patients. The Kruskal-Wallis Test was performed to test for differences between the three groups.
The Wilcoxon Rank-Sum Test was performed to test for differences between two groups of participants.
Median Level (range) Overall Test (p-
value)
Pairwise-Test (p-value)
Characteristic
of study
participants
Control T2D MetS Control vs T2D&MetS Control vs T2D Control vs MetS MetS vs T2D
Age (Years) 71
(47–85)
69
(50–85)
76
(45–81)
0.99 0.93 0.99 0.85 1.00
Gender Female 7 (64%) 10 (40%) 5 (56%) 0.50 0.34 0.27 0.79 0.51
Male 4 (36%) 15 (60%) 4 (44%)
Fasting blood
glucose (mg/dl)
84
(69–100)
158
(99–351)
97
(87–158)
<0.01* <0.01* <0.01* 0.01* <0.01*
Diastolic blood
pressure
(mmHg)
80
(60–90)
80
(50–100)
80
(70–90)
0.85 0.73 0.87 0.53 0.72
Systolic blood
pressure
(mmHg)
130
(110–
150)
140
(100–
170)
135
(120–
170)
0.30 0.13 0.16 0.20 0.98
HDL cholesterol
(mg/dl)
59
(26–92)
40
(15–69)
55
(33–91)
0.01* 0.01* <0.01* 0.54 0.05*
Triglycerides
(mg/dl)
109
(65–209)
190
(100–
637)
164
(116–
285)
0.01* <0.01* <0.01* 0.03* 0.60
Waist
measurement
(cm)
86
(69–103)
110
(89–152)
92
(82–110)
<0.01* <0.01* <0.01* 0.06 0.01*
*p0.05
https://doi.org/10.1371/journal.pone.0180955.t001
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(Zymo Research, Irvine, CA, USA), according to manufacturer’s recommendation. The sam-
ples were amplified in 20μl reactions, containing 10μl of Hot StarTaq Master Mix (Qiagen, Hil-
den, Germany), 150ng of each primer and ~ 20ng modified DNA.
PCR was performed with one cycle of 95˚C for 15 min, 40 cycles of 95˚C for 30 sec, 57–
63˚C for 30 sec and 72˚C for 30 sec, followed by one cycle of 72˚C for 5 min. For each set of
primers one of the primers included a 5’-biotin label to allow subsequent analysis by pyrose-
quencing (S1 Table).
Primer sequences were either previously published[12,28–30] or designed using the primer
design program ‘PSQ assay’ (Biotage), using gene sequences that were obtained from the Gen-
Bank entry on NCBI. Primers were designed near the transcriptional start site of the gene and
in an area free of SNPs. One pair of primers was designed per gene. CpG coverage varied
between 3 and 9 loci per gene within a length of maximum 41 basepairs (S1 Table). Our candi-
date genes were located on different chromosomes. KCNJ11 and KCNQ1 can be found on
chromosome 11, with our primers covering chromosomal positions 17,411,485–17,411,507
and 2,721,948–2,721,988, respectively. The PPARγ primers covered the area that can be found
on chromosome 3:12,288,073–12,288,089, PDK4 on chromosome 7:95,584,377–95,584,395,
SCD1 on chromosome 10:100,347,893–100,347,934, PDX1 on chromosome 13:27,920,513–
27,920,543, FTO on chromosome 16:53,704,013–53,704,036 and PEG3 on chromosome
19:56,810,083–56,810,100. For an overview of the primer information and specific CpG posi-
tions, see S1 Table.
DNA methylation analysis
Pyrosequencing was performed on a PyroMark Q24 MD pyrosequencer (Qiagen, Hilden, Ger-
many), according to manufacturer’s recommendation. Pyrosequencing analyses were per-
formed in duplicate. If the duplicates of the individual samples showed a difference < 2% of
methylation, the average methylation of the two measurements was used for further analyses.
When the difference was >2% a third measurement was performed.
Assay validation was carried out on samples of known methylation status, which were cre-
ated from whole genome amplified DNA, representing hypomethylation, and DNA treated
with CpG methyltransferase M.SssI, representing hypermethylation (New England Biolabs,
Ipswich, MA, USA). Each PCR plate contained the participants’ DNA samples, as well as three
dH2O samples as non-template controls and three samples with known methylation status as
positive controls. The quality of the pyrosequencing assays were analysed using the internal
control of the pyrosequencer and the pyrograms. Reproducibility of the pyrosequencing runs
was high for all the assays included in this study.
Statistical analysis
Gene methylation was calculated by determining the average methylation level across the CpG
loci per gene. Methylation data were not normally distributed and therefore the nonparametric
Kruskal-Wallis test was used to identify significant differences between the three subgroups
and the Wilcoxon Rank-Sum Test to perform pairwise comparisons between two groups.
These analyses were performed on both the average gene methylation data and the methyla-
tion data of the individual CpG loci. A Spearman correlation was performed to identify corre-
lations between measurements. All analyses were conducted using R version 3.2.2 software
and visualized using the ggplot2 package[31].
The methylation analyses were performed without prior knowledge of the participant
characteristics.
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Results
Differential DNA methylation between patient groups
Differences in DNA methylation levels between the three subgroups were small and did not
reach statistical significance for any of the genes, although a trend towards significance was
observed for the PEG3 gene (p = 0.07) (Fig 1 and Table 2). A similar trend toward significance
Fig 1. Differences in candidate gene methylation between controls, T2D and MetS participants. Overall gene specific DNA methylation levels are
shown per group of participants.
https://doi.org/10.1371/journal.pone.0180955.g001
Table 2. Differences in candidate gene methylation between controls, T2D and MetS participants. Gene specific DNA methylation levels are shown as
median (range). The Kruskal-Wallis Test was performed to test for differences between the three groups. The Wilcoxon Rank-Sum Test was performed to test
for differences between two groups of participants.
Median Methylation Level (range)(%) Overall Test
(p-value)
Pairwise-Test (p-value)
Gene Control T2D MetS Control vs T2D&MetS Control vs T2D Control vs MetS MetS vs T2D
FTO 2.8
(1.6–4. 39)
3.0
(1.4–5.6)
3.0
(1.9–6.3)
0.40 0.32 0.24 0.26 0.79
KCNJ11 5.0
(2.2–15.7)
4.7
(2.4–6.3)
4.3
(1.9–5.0)
0.21 0.87 0.77 0.16 0.10
KCNQ1 36.0
(34.2–38.4)
35.9
(29.9–39.3)
34.8
(32.1–38.1)
0.28 0.43 0.97 0.18 0.15
PDK4 35.3
(24.5–48.3)
31.2
(21.9–52.2)
34.0
(27.2–40.9)
0.68 0.64 0.39 0.94 0.68
PDX1 5.5
(3.5–8.4)
6.1
(2.3–8.1)
5.2
(4.4–7.1)
0.47 0.20 0.36 0.46 0.36
PEG3 36.6
(33.5–52.3)
36.1
(29.2–43.1)
37.7
(34.2–61.8)
0.07 0.07 0.18 0.54 0.03*
PPARγ 10.1
(8.2–13.2)
11.0
(7.6–21.0)
11.5
(9.2–16.2)
0.41 0.12 0.41 0.20 0.49
SCD1 6.4
(5.1–17.6)
6.67
(5.3–9.3)
6.6
(4.5–7.6)
0.66 0.30 0.42 0.57 0.69
*p0.05
https://doi.org/10.1371/journal.pone.0180955.t002
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was observed for this gene between the controls and all metabolic patients (i.e. the MetS and
T2D patients) (p = 0.07). Further analyses of PEG3 methylation revealed that significantly
higher levels of methylation of 1.5 percentage points were observed in the MetS patients com-
pared to the T2D patients (p = 0.03). These statistical differences in PEG3 methylation were
mainly driven by three outliers with methylation levels greater than 50%; two MetS patients
and one control subject. Excluding these outliers resulted in a loss of statistical significance,
although a trend towards significance was still observed (p = 0.051). Interestingly, the two
MetS patients with the highest levels of PEG3 methylation also had high levels of PDX1 and
FTOmethylation.
Further investigation into individual CpG loci revealed no statistical differences in DNA
methylation levels between the T2D and MetS patients and the control participants. However,
after dividing the patients into the MetS or T2D subgroups, some loci were observed to be dif-
ferentially methylated. These specific CpG loci were found in the FTO,KCNJ11 and PPARγ
genes. One CpG locus out of the 7 loci in the FTO gene indicated differential methylation
between the MetS patients and the controls (p = 0.01), with median methylation levels of 2.7%
and 2.1% respectively, while another CpG locus in the FTO gene was tending toward signifi-
cance between the T2D patients and the controls (p = 0.07). 1 CpG locus out of the 4 loci in
the PPARγ gene was significantly higher methylated in the T2D patients compared to the con-
trols, with an average increase of 3.5 percentage points in the T2D patient group (p = 0.05).
One out of the 3 loci in the KCNJ11 gene was differentially methylated between the T2D and
MetS patients. For this CpG locus, the MetS patient group had DNA methylation levels that
were on average 1.4 percentage points higher than the methylation levels observed for the
T2D patient group (p<0.01). In comparison, the control group had median methylation levels
that were on average 1.3 percentage points lower than the MetS group and was tending to-
wards significance (p = 0.08)(Table 3). One CpG locus out of the 4 loci in the PDK4 gene was
significantly lower methylated in the T2D and MetS patient groups than in the control group
(p = 0.048). The T2D and MetS patient groups had average methylation levels that were 5.7
percentage points lower than the average methylation levels observed in the control group. A
trend towards significance was observed for this CpG locus between the control group and the
Table 3. DNA methylation levels of individual CpG loci located in the KCNJ11, PPARγ, FTO and PDK4 genes. DNA methylation levels of specific CpG
loci are shown as median (range). The Kruskal-Wallis Test was performed to test for differences between the three groups. The Wilcoxon Rank-Sum Test
was performed to test for differences between two groups of participants. DNA methylation levels of individual CpG loci, located in the genes KCNJ11,
PPARγ, FTO and PDK4 were significantly different between groups of participants (p0.05). None of the other CpG loci included in this study were signifi-
cantly different between our groups of participants (S2 Table).
Median Methylation Level (range)(%) Overall Test
(p-value)
Pairwise-Test (p-value)
CpG loci Control T2D MetS Control vs T2D&MetS Control vs MetS Control vs T2D MetS vs T2D
KCNJ11 CpG2
(Chr11:17,411,502)
6.9
(6.0–9. 9)
6.8
(5.7–8.6)
8.2
(6.2–10.2)
0.17 0.34 0.08 0.27 <0.01*
PPARγ CpG1
(Chr3:12,288,073)
7.0
(5.6–12.5)
10.5
(6.5–15.0)
9.2
(5.0–21.3)
0.20 0.13 0.18 0.05* 0.66
FTO CpG5
(Chr16: 53,704,031)
2.3
(1.2–5.4)
3.1
(1.0–7.7)
2.8
(1.6–6.3)
0.20 0.19 0.13 0.07 0.74
FTO CpG6
(Chr16: 53,704,034)
2.1
(0.9–2.8)
2.3
(0.9–7.2)
2.7
(1.2–7.8)
0.19 0.32 0.01* 0.11 0.21
PDK4 CpG1
(Chr7: 95,584,377)
56.8
(38.1–80.2)
50.7
(34.8–81.6)
53.2
(45.2–64.9)
0.37 0.05* 0.15 0.05 0.94
PDK4 CpG4
(Chr7:95,584,395)
27.5
(20.4–37.4)
23.4
(18.2–63.4)
25.9
(20.4–32.8)
0.64 0.06 0.05 0.12 0.27
*p0.05
https://doi.org/10.1371/journal.pone.0180955.t003
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patient group that was diagnosed with only T2D (p = 0.05), but not with the group that was
diagnosed with MetS (p = 0.15)(Table 3). A trend towards a significant difference was observed
for another Cpg locus in this gene between the control group and the T2D and MetS patient
groups (p = 0.06). This trend towards significance was also observed when comparing the con-
trol group to the MetS group (p = 0.05), but not when comparing the control group to the
group that was diagnosed with only T2D (Table 3).
None of the other CpG loci included in our analyses reached statistical significant differ-
ences in DNA methylation levels between our groups of participants (S2 Table).
Correlations between DNA methylation and characteristics of study
participants
To study a possible correlation between DNA methylation levels and characteristics of study
participants, a Spearman’s correlation was performed (Fig 2). These analyses revealed statisti-
cally significant correlations between HDL cholesterol, waist measurements and fasting blood
glucose levels and PEG3 methylation (Spearman’s correlation, p<0.05) such that individuals
with higher levels of HDL cholesterol, lower levels of fasting blood glucose levels, and lower
waist measurements had higher methylation levels of PEG3. Further analyses revealed that
these correlations were mainly driven by the three outliers with methylation levels greater than
50%. Two of these three outliers were located in the highest quadrantile for HDL cholesterol,
and all three were in the lower quadrantile for both waist measurement and fasting glucose lev-
els. Exclusion of these outliers resulted in a loss of statistical significance, although a positive
trend remained between PEG3 methylation and HDL cholesterol (p = 0.05). Further analyses
Fig 2. Correlations between DNA methylation and characteristics of study participants. Gene specific DNA methylation levels are shown relative to
patient characteristics.
https://doi.org/10.1371/journal.pone.0180955.g002
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revealed that the correlation between PEG3 methylation and HDL cholesterol was strongest in
the control group (R2 = 0.743).
None of the other genes revealed a correlation between methylation levels and either one of
the characteristics of the study participants assessed.
Discussion
In this study we analysed DNA methylation levels of a subset of candidate genes in PBL from
patients diagnosed with T2D or MetS and control subjects without a metabolic disorder. All of
the genes analysed in this study were previously reported to have a potential importance in the
development of metabolic diseases and play critical roles in glucose metabolism, adipogenesis
and/or insulin secretion[21–26]. Differential methylation was observed in previous studies for
most of these genes between patients diagnosed with either T2D or MetS and control subjects
in adipose tissues, muscles and/or pancreatic islets[12–16,28]. Our analyses in PBLs revealed
no significant difference in methylation levels between the MetS patients, T2D patients and
controls subjects, although a trend towards significance was observed for PEG3. A trend
towards a positive correlation was also observed for PEG3 methylation with HDL cholesterol
levels. PEG3 is a mediator of p53, which in turn directly influences various metabolic path-
ways, enabling cells to respond to metabolic stress. These functions are likely to be important
for restraining the development of cancer but may also have a profound effect on the develop-
ment of metabolic diseases, including diabetes. p53 plays a role in central carbon and lipid
metabolism and it downregulates HDL[32,33]. As a mediator of P53, PEG3 methylation may
contribute to the development of metabolic dysfunction by altering the response of cells to
metabolic stress. Our study suggests that altered PEG3 DNA methylation may be present in
PBL of patients with a metabolic disorder. Unfortunately our study only included 45 individu-
als, so additional studies are necessary to explore this relation in greater detail.
Even though none of the genes revealed statistically significant gene specific differences in
DNA methylation between the groups of participants, differences were observed in individual
CpG loci. For example, methylation of one locus in the KCNJ11 gene was significantly higher
in the MetS group than in the T2D group and was tending towards significance compared to
the control group. Genetic defects in the KCNJ11 gene have been previously associated with an
increased risk of diabetic disorders and heart failure, by inducing changes in the heart’s
response to stress[34,35]. In line with these reports, we could speculate that the elevated levels
of DNA methylation in the MetS patient group for this KCNJ11 CpG locus may mimic the
genetic defects in the KCNJ11 gene. We do not have detailed information about the genetic
predispositions of our study population, so this remains speculation and further investigation
is required to study this potential in greater detail, although similar mechanisms have been
observed in cancer, where hypermethylation in sporadic cancers is frequently observed in the
same genes that are mutated in familial cancers [36–39].
DNA methylation levels of one CpG locus in the PPARγ gene was significantly increased in
the T2D group compared to the control group. Animal knock-out studies have suggested that
PPARγ contributes to insulin resistance and PPARγ agonists are used in the treatment of T2D
[40–42]. A study by Dave´ et al reported that correlations between PPARγ DNA methylation
and PPARγ expression were observed for several CpG loci located in the PPARγ gene, even for
loci located in the gene body[43]. As a result, reduced gene activity of the PPARγ gene may be
another possible pathway in which PPARγ affects the development of T2D. Even though all of
our MetS patients were diagnosed with T2D, a similar trend was not observed between the
MetS patients and the control subjects.
DNA methylation in blood from patients with T2D or MetS
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One CpG locus located in the PDK4 gene was significantly differentially methylated
between our T2D and MetS patients and the control group, while another CpG locus was tend-
ing towards a significant difference. DNA methylation levels in the T2D and MetS patient
groups were lower than the DNA methylation levels observed in the control group for both of
these loci. PDK4 is reported to contribute to the regulation of glucose metabolism and mito-
chondrial function and lower levels of PDK4 DNA methylation, in combination with increased
levels of PDK4 expression, were previously observed in skeleton muscle of diabetic patients
compared to a control group[15]. Our results suggest that similar alterations of DNA methyla-
tion patterns may also be present in PBL.
Another CpG locus in our study with significantly increased levels of DNA methylation in
the MetS patients compared to the control subjects was located in the FTO gene, while another
locus in this gene was tending towards a significant difference between the control group and
the T2D patients. A previous study performed by Toperoff et al suggested that FTOwas differ-
entially methylated in PBLs from diabetic patients compared to non-diabetic patients in an
epigenome-wide association study[44]. Another study by the same group suggested that a
methylation difference between diabetic patients and controls for one CpG locus located in a
region within an intron of the FTO gene, was apparent in young subjects, but no longer existed
at older ages[45]. Even though our study investigated a different FTO region than the study by
Toperoff et al, and our study population was remarkably older, we did observe differential
DNA methylation in a CpG locus located in the FTO gene, suggesting a potential of FTO gene
methylation in PBL as a biomarker of T2D or MetS.
None of the other CpG loci included in our study revealed differential levels of DNA meth-
ylation in PBL between our groups of participants. This is in line with a previously published
study by Arner et al, who performed an epigenome-wide association study including periph-
eral blood mononuclear cells from 80 obese female participants with and without insulin resis-
tance[46]. Arner et al did not observe significant differentially methylated loci between those
individuals identified with and without insulin resistance, although some loci were nominally
significant[46]. From those nominally differentially methylated loci, one locus was located in
the gene body region of KCNQ1, while none of the other loci were located in close proximity
of our investigated gene regions.
Most of the candidate genes included in our study were previously reported to show differ-
ential levels of DNA methylation in other tissues. For example, increased levels of PDX1 DNA
methylation, in combination with decreased PDX1 expression levels, were observed in pancre-
atic islets from patients diagnosed with T2D compared to a control group[12], while we did
not observed differences in DNA methylation levels for this gene between our T2D diabetes
patients and controls in PBL. This suggests that altered levels of DNA methylation for these
genes may be tissue type specific.
There are a few limitations in our study which could also have affected our findings. First of
all, we have only measured between 3 and 9 CpG loci per gene and it is possible that other
CpG loci located in our candidate genes are differently methylated between our groups of par-
ticipants. For example, in a genome-wide association study, differentially methylated loci were
observed in PBLs from pooled T2D patients versus controls in a genome-wide association
study for 3 loci located in the intronic regions of the KCNQ1[44], while none of the CpG loci
included for this gene in our study reached statistical significance. Secondly, with our study
population having a mean age of 70 years, it is well possible that larger differences in methyla-
tion levels between the different groups would have been observed in a younger population,
where age-related decline of metabolic functions might not yet be as substantial. The correla-
tion between age and DNA methylation is well established[47] and Toperoff et al reported a
loss of significant differences in DNA methylation levels of the FTO gene between T2D
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patients and controls with an increasing age[45]. As a result, it is possible that differential
DNA methylation between the T2D and MetS patients and controls of our candidate genes
would be more apparent in a younger population. Thirdly, our study population included only
45 participants and may thus be too small to detect differential DNA methylation and strong
associations with characteristics of study participants. We have also only investigated a smaller
number of genes and CpG loci in this study and the difference in DNA methylation levels
between the groups of participants was small. As a result, it is possible that our findings were
due to random sampling errors and are not biologically reproducible.
Further investigation into differential methylation between metabolic patients and healthy
controls remains necessary and epigenome-wide analyses could reveal other genes with altered
levels of methylation in T2D or MetS in PBLs. Several other genes, including CIDEP, FABP3,
FFAR, CCL2 and PRKCZ, have previously been identified to be differentially methylated in
PBLs from diabetic patients[48–51] and could thus be of potential in the identification of met-
abolic diseases. Associations between altered levels of DNA methylation and gene expression
were observed in T2D patients in several tissues, including PBL[13,16,51,52], which further
supports the potential role of DNA methylation in metabolic diseases.
Our current observations do not allow determining the timing of the observed differential
methylation. As a result, it remains unknown whether differential methylation is present
before the development of the disease, and thus potentially plays a role in the development, or
if it is merely a consequence of the disease. One study observed differential DNA methylation
in blood in the pre-T2D state[20], suggesting that DNA methylation may be precoding T2D,
and thus be present before the development of the disease. This suggests that differential meth-
ylation in PBLs might be a hallmark of T2D and MetS and may be used as a tool to identify
these metabolic conditions. Differences in methylation levels between T2D and MetS patients
were present in one KCNJ11 locus included in our study, suggesting that in patients with
increased insulin resistance, or who are already diagnosed with T2D, DNA methylation might
be used as a biomarker for other metabolic conditions, such as MetS. Although this associa-
tions was only found in a single loci and further study is necessary to determine to strength of
this association.
In conclusion, our study reports a trend towards significance between PEG3 DNA meth-
ylation levels in PBLs in the MetS and the T2D patients versus the controls and 4 out of the
42 CpG loci included in this study were differentially methylated between groups of partici-
pants. As a result, altered levels of DNA methylation in PBLs of these loci might serve as a bio-
marker for T2D or MetS, although additional research is required to further strengthen these
observations.
Supporting information
S1 Fig. Correlations between study participant characteristics. The lower triangle contains
pair-wise characteristic of study participant scatterplots.
The upper triangle shows the spearman correlation between characteristic of study partici-
pants. The colour corresponds to the strength of the correlation, with the dark red colour indi-
cating the strongest correlation.
p<0.05, p<0.001.
(TIF)
S1 Table. Primer and gene information. Primer sequences and CpG locations for the loci
included in this study.
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S2 Table. DNA methylation levels of individual CpG loci. DNA methylation levels of specific
CpG loci are shown as median (range). The Kruskal-Wallis Test was performed to test for dif-
ferences between the three groups. The Wilcoxon Rank-Sum Test was performed to test for
differences between two groups of participants.
p0.05.
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